open access

Vol 25, No 6 (2020)
Published online: 2020-11-01
Submitted: 2020-04-02
Get Citation

Octreotide in the treatment of malignant thymoma – Case report

Ondrej Sorejs, Milos Pesek, Jindrich Finek, Ondrej Fiala
DOI: 10.1016/j.rpor.2020.08.012
·
Rep Pract Oncol Radiother 2020;25(6):882-885.

open access

Vol 25, No 6 (2020)
Published online: 2020-11-01
Submitted: 2020-04-02

Abstract

Thymomas are the most common mediastinal tumors. Systemic therapy for patients with unresectable or recurrent thymomas is a challenging field in the current oncology research. There is some evidence that somatostatin analogs combined with corticosteroids may have a role in the treatment of advanced malignant thymoma; however, the role of these agents have not been fully evaluated.

Case report

A 39-year-old man with metastatic thymoma was administered long-acting depot injection form of octreotide. Octreotide scan before the treatment initiation revealed low uptake. CT control after three months of the treatment revealed marked regression of pleural metastases, while the primary tumor mass remained stable. The treatment response was lasting for 9 months.

Conclusion

We describe an interesting case of marked clinical and radiological response of advanced malignant thymoma to the treatment with octreotide in a heavily pre-treated patient, even though octreotide scan revealed low uptake.

Abstract

Thymomas are the most common mediastinal tumors. Systemic therapy for patients with unresectable or recurrent thymomas is a challenging field in the current oncology research. There is some evidence that somatostatin analogs combined with corticosteroids may have a role in the treatment of advanced malignant thymoma; however, the role of these agents have not been fully evaluated.

Case report

A 39-year-old man with metastatic thymoma was administered long-acting depot injection form of octreotide. Octreotide scan before the treatment initiation revealed low uptake. CT control after three months of the treatment revealed marked regression of pleural metastases, while the primary tumor mass remained stable. The treatment response was lasting for 9 months.

Conclusion

We describe an interesting case of marked clinical and radiological response of advanced malignant thymoma to the treatment with octreotide in a heavily pre-treated patient, even though octreotide scan revealed low uptake.

Get Citation

Keywords

Thymoma; Octreotide; Treatment; Somatostatin analog; Case report

About this article
Title

Octreotide in the treatment of malignant thymoma – Case report

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 25, No 6 (2020)

Pages

882-885

Published online

2020-11-01

DOI

10.1016/j.rpor.2020.08.012

Bibliographic record

Rep Pract Oncol Radiother 2020;25(6):882-885.

Keywords

Thymoma
Octreotide
Treatment
Somatostatin analog
Case report

Authors

Ondrej Sorejs
Milos Pesek
Jindrich Finek
Ondrej Fiala

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl